> ## Content Index
> Fetch the complete content index at: https://www.sharespective.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# A six-month eye injection nearly tripled Kodiak Sciences in a day
- URL: https://www.sharespective.com/stories/six-month-eye-injection-nearly-tripled-2026-09-29/
- Published: 2026-09-28T21:15:00.000Z
- Updated: 2026-10-19T19:28:19.000Z
- Description: Kodiak Sciences closed at US$87.70 on Monday, up 177.96%. Its drug Zenkuda hit the primary endpoint of the phase 3 DAYBREAK study in wet age-related macular degeneration, at a p-value of 0.0007.
- Author: Shaun Botha
- Tags: Biotech, #story, #group-health, Kodiak Sciences

Kodiak Sciences closed at US$87.70 on Monday, up 177.96%. Its drug Zenkuda hit the primary endpoint of the phase 3 DAYBREAK study in wet age-related macular degeneration, at a p-value of 0.0007.

**The number that matters is the gap between appointments.** Regeneron's aflibercept, the standard treatment, goes into the eye about every two months. In the trial, 54% of patients on Zenkuda reached a 24-week gap by the end of the first year.

Every two months is about six injections a year. A 24-week gap is two. For a patient in their seventies, and for whoever drives them to the clinic, that is the whole difference.

Zenkuda matched aflibercept on vision gains at one year rather than beating it, which is the bar these studies are built to clear. A second candidate, tabirafusp-ted, also met its vision endpoint, at a p-value of 0.0036.

Kodiak now plans to file for approval in the fourth quarter, across wet AMD, diabetic retinopathy and retinal vein occlusion, on the strength of five positive phase 3 studies.

The tell 

the label. A six-month interval on non-inferior data is a commercial argument, and it only works if the regulator lets Kodiak print that interval on the box. That decision sits a long way from Monday's share price.

[ This story ran in The Yield Did It Tuesday 29 September’s edition, with the market snapshot, the other two stories, the numbers and the week ahead. Read the whole edition → ](https://www.sharespective.com/sharespective-2026-09-29/)